Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J.-D.[Kim, J.-D.] | - |
dc.contributor.author | Park, C.-Y.[Park, C.-Y.] | - |
dc.contributor.author | Cha, B.-Y.[Cha, B.-Y.] | - |
dc.contributor.author | Ahn, K.J.[Ahn, K.J.] | - |
dc.contributor.author | Kim, I.J.[Kim, I.J.] | - |
dc.contributor.author | Park, K.S.[Park, K.S.] | - |
dc.contributor.author | Lee, H.W.[Lee, H.W.] | - |
dc.contributor.author | Min, K.-W.[Min, K.-W.] | - |
dc.contributor.author | Won, J.C.[Won, J.C.] | - |
dc.contributor.author | Chung, M.Y.[Chung, M.Y.] | - |
dc.contributor.author | Kim, J.-T.[Kim, J.-T.] | - |
dc.contributor.author | Kang, J.G.[Kang, J.G.] | - |
dc.contributor.author | Park, S.-W.[Park, S.-W.] | - |
dc.date.accessioned | 2021-07-29T23:46:34Z | - |
dc.date.available | 2021-07-29T23:46:34Z | - |
dc.date.created | 2019-01-07 | - |
dc.date.issued | 2018-05 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/24378 | - |
dc.description.abstract | Purpose: The purpose of this study was to compare the adherence of the glimepiride/metformin sustained release (GM-SR) once-daily fixed-dose combination and glimepiride/metformin immediate release (GM-IR) BID fixed-dose combination in type 2 diabetes therapies. Methods: An open-label, randomized, multicenter, parallel-group study was conducted at 11 hospitals in the Republic of Korea. A total of 168 patients with type 2 diabetes treated with >4 mg of glimepiride and 1000 mg of metformin by using free or fixed-dose combination therapy for at least 2 weeks were enrolled. Patients were randomized to receive GM-SR 4/1000 mg once-daily or GM-IR 2/500 mg BID for 24 weeks. Adherence was compared by using the Medication Event Monitoring System (MEMS). Findings: A significant difference in adherence was observed between the 2 groups. Overall adherence, defined by the number of container openings divided by the number of prescribed doses, was 91.7% in the GM-SR group and 88.6% in the GM-IR group (P < 0.001). The percentage of treatment days with the correct number of doses taken was 85.3% in the GM-SR group and 75.1% in the GM-IR group (P < 0.001). The percentage of missed doses was 11.7% in the GM-SR group and 15.3% in the GM-IR group (P < 0.001). The percentage of doses taken in the correct time window and therapeutic coverage were higher in the GM-SR group (P < 0.001). There was no significant difference in glycosylated hemoglobin changes or number of adverse events between the 2 groups. A total of 168 patients randomized to receive GM-SR once daily (86 patients) or GM-IR twice daily (82 patients). Mean Age were 57.8 ± 9.6 years old. Male: female ratio was 47.6: 52.4 %. Body mass index were 66.3 ± 12.0 kg/m2, Diabetes duration were 10.5 ± 6.6 years. Implications: This study showed that patient adherence with GM-SR once daily was significantly better than with GM-IR BID. ClinicalTrials.gov identifier: NCT01620489. © 2018 Elsevier HS Journals, Inc. | - |
dc.publisher | Excerpta Medica Inc. | - |
dc.title | Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, C.-Y.[Park, C.-Y.] | - |
dc.contributor.affiliatedAuthor | Park, S.-W.[Park, S.-W.] | - |
dc.identifier.doi | 10.1016/j.clinthera.2018.04.002 | - |
dc.identifier.scopusid | 2-s2.0-85046780180 | - |
dc.identifier.wosid | 000433380100009 | - |
dc.identifier.bibliographicCitation | Clinical Therapeutics, v.40, no.5, pp.752 - 761.e2 | - |
dc.relation.isPartOf | Clinical Therapeutics | - |
dc.citation.title | Clinical Therapeutics | - |
dc.citation.volume | 40 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 752 | - |
dc.citation.endPage | 761.e2 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ANTIRETROVIRAL THERAPY | - |
dc.subject.keywordPlus | REPORTED ADHERENCE | - |
dc.subject.keywordPlus | DISORDER | - |
dc.subject.keywordPlus | FREQUENCY | - |
dc.subject.keywordPlus | ADULTS | - |
dc.subject.keywordAuthor | fixed dose combination | - |
dc.subject.keywordAuthor | glimepiride | - |
dc.subject.keywordAuthor | MEMS | - |
dc.subject.keywordAuthor | sulfonylurea | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.